Manufacturer of Controlled Substances; Notice of Application, 13825 [E7-5400]
Download as PDF
Federal Register / Vol. 72, No. 56 / Friday, March 23, 2007 / Notices
Organix Inc to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Organix
Inc to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: March 19, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–5403 Filed 3–22–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Alexandria, Virginia 22301; and must be
filed no later than May 22, 2007.
DEPARTMENT OF LABOR
Dated: March 19, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–5400 Filed 3–22–07; 8:45 am]
Occupational Safety and Health
Administration
BILLING CODE 4410–09–P
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on December 7, 2006,
Sigma Aldrich Research, Biochemicals,
Inc., 1–3 Strathmore Road, Natick,
Massachusetts 01760, made application
by letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedule I:
sroberts on PROD1PC70 with NOTICES
Manufacturer of Controlled
Substances; Notice of Application
Drug
VerDate Aug<31>2005
16:41 Mar 22, 2007
Jkt 211001
Schedule
Psilocybin (7437) ..........................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
I
I
The company plans on manufacturing
reference standards for research
purposes only.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA ≤Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than May 22, 2007.
Dated: March 9, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–5391 Filed 3–22–07; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
[Docket No. OSHA–2007–0025]
Derricks; Extension of the Office of
Management and Budget’s (OMB)
Approval of Information Collection
(Paperwork) Requirements
Occupational Safety and Health
Administration (OSHA), Labor.
ACTION: Request for public comment.
AGENCY:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on January 31, 2007,
Penick Corporation, 33 Industrial Park
Road, Pennsville, New Jersey 08070,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Poppy Straw Concentrate (9670), a basic
class of controlled substance listed in
schedule II:
The company plans on manufacturing
Poppy Straw Concentrate for internal
use and on manufacturing other bulk
controlled substance intermediates for
sale to their customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration, Attention:
DEA Federal Register Representative/
ODL, Washington, DC 20537; or any
being sent via express mail should be
sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
13825
SUMMARY: OSHA solicits public
comment concerning its proposal to
extend OMB approval of the
information collection requirements
specified in its Standard on Derricks (29
CFR 1910.181).
DATES: Comments must be submitted
(postmarked, sent, or received) by May
22, 2007.
ADDRESSES:
Electronically: You may submit
comments and attachments
electronically at https://
www.regulations.gov, which is the
Federal eRulemaking Portal. Follow the
instructions online for submitting
comments.
Facsimile: If your comments,
including attachments, are not longer
than 10 pages, you may fax them to the
OSHA Docket Office at (202) 693–1648.
Mail, hand delivery, express mail,
messenger, or courier service: When
using this method, you must submit
three copies of your comments and
attachments to the OSHA Docket Office,
OSHA Docket No. OSHA–2007–0025,
U.S. Department of Labor, Occupational
Safety and Health Administration,
Room N–2625, 200 Constitution
Avenue, NW., Washington, DC 20210.
Deliveries (hand, express mail,
messenger, and courier service) are
accepted during the Department of
Labor’s and Docket Office’s normal
business hours, 8:15 a.m. to 4:45 p.m.,
e.t.
Instructions: All submissions must
include the Agency name and OSHA
docket number for the ICR (OSHA–
2007–0025). All comments, including
any personal information you provide,
are placed in the public docket without
change, and may be made available
online at https://www.regulations.gov.
For further information on submitting
comments see the ‘‘Public
Participation’’ heading in the section of
this notice titled SUPPLEMENTARY
INFORMATION.
Docket: To read or download
comments or other material in the
docket, go to https://www.regulations.gov
E:\FR\FM\23MRN1.SGM
23MRN1
Agencies
[Federal Register Volume 72, Number 56 (Friday, March 23, 2007)]
[Notices]
[Page 13825]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-5400]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on January 31, 2007, Penick
Corporation, 33 Industrial Park Road, Pennsville, New Jersey 08070,
made application by letter to the Drug Enforcement Administration (DEA)
to be registered as a bulk manufacturer of Poppy Straw Concentrate
(9670), a basic class of controlled substance listed in schedule II:
The company plans on manufacturing Poppy Straw Concentrate for
internal use and on manufacturing other bulk controlled substance
intermediates for sale to their customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODL,
Washington, DC 20537; or any being sent via express mail should be sent
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must
be filed no later than May 22, 2007.
Dated: March 19, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-5400 Filed 3-22-07; 8:45 am]
BILLING CODE 4410-09-P